User profiles for JEEYUN LEE

Jeeyun Lee (이지연)

Samsung Medical Center 삼성서울병원
Verified email at skku.edu
Cited by 101647

Comprehensive molecular characterization of clinical responses to PD-1 inhibition in metastatic gastric cancer

…, K Kim, XQ Liu, X Sher, H Jung, M Lee, S Lee… - Nature medicine, 2018 - nature.com
Clinical studies support the efficacy of programmed cell death 1 (PD-1) targeted therapy in a
subset of patients with metastatic gastric cancer (mGC). With the goal of identifying …

[HTML][HTML] Trastuzumab deruxtecan in previously treated HER2-positive gastric cancer

…, H Kawakami, H Yabusaki, J Lee… - … England Journal of …, 2020 - Mass Medical Soc
Background Trastuzumab deruxtecan (DS-8201) is an antibody-drug conjugate consisting
of an anti-HER2 (human epidermal growth factor receptor 2) antibody, a cleavable …

Individual patient data meta-analysis of the value of microsatellite instability as a biomarker in gastric cancer

…, M Di Bartolomeo, D Cunningham, J Lee… - Journal of Clinical …, 2019 - discovery.ucl.ac.uk
PURPOSE: In the CLASSIC and MAGIC trials, microsatellite instability (MSI)–high status
was a favorable prognostic and potential negative predictive factor for neoadjuvant/adjuvant …

Molecular analysis of gastric cancer identifies subtypes associated with distinct clinical outcomes

R Cristescu, J Lee, M Nebozhyn, KM Kim, JC Ting… - Nature medicine, 2015 - nature.com
Gastric cancer, a leading cause of cancer-related deaths, is a heterogeneous disease. We
aim to establish clinically relevant molecular subtypes that would encompass this …

Efficacy and safety of pembrolizumab or pembrolizumab plus chemotherapy vs chemotherapy alone for patients with first-line, advanced gastric cancer: the KEYNOTE …

…, KW Lee, I Kudaba, M Garrido, HC Chung, J Lee… - JAMA …, 2020 - jamanetwork.com
Importance Safe and effective therapies for untreated, advanced gastric/gastroesophageal
junction (G/GEJ) cancer remain an unmet need. Objective To evaluate the antitumor activity of …

Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label …

…, P Ruff, C Jacobs, G Landers, W Szpak, SY Roh, J Lee… - The Lancet, 2018 - thelancet.com
Background Patients with advanced gastric or gastro-oesophageal junction cancer that
progresses on chemotherapy have poor outcomes. We compared pembrolizumab with paclitaxel …

[PDF][PDF] Phase III trial comparing capecitabine plus cisplatin versus capecitabine plus cisplatin with concurrent capecitabine radiotherapy in completely resected gastric …

J Lee, DH Lim, S Kim, SH Park, JO Park, YS Park… - J clin oncol, 2012 - academia.edu
Purpose The ARTIST (Adjuvant Chemoradiation Therapy in Stomach Cancer) trial was the
first study to our knowledge to investigate the role of postoperative chemoradiotherapy …

[PDF][PDF] Phase III trial to compare adjuvant chemotherapy with capecitabine and cisplatin versus concurrent chemoradiotherapy in gastric cancer: final report of the …

SH Park, TS Sohn, J Lee, DH Lim, ME Hong… - Journal of clinical …, 2015 - niioncologii.ru
… Collection and assembly of data: Se Hoon Park, Min Eui Hong, Kyoung-Mee Kim, Min Gew
Choi, Jun Ho Lee, Jae Moon Bae, Jeeyun Lee, Joon Oh Park, Young Suk Park, Ho Yeong Lim …

Extranodal natural killer T-cell lymphoma, nasal-type: a prognostic model from a retrospective multicenter study

…, YH Park, YH Ko, SM Bang, JH Lee, DH Lee… - Journal of clinical …, 2006 - ascopubs.org
Purpose Patients with natural killer T (NK/T) -cell lymphomas have poor survival outcome,
and for this condition there is no optimal therapy. The purpose of this study was to design a …

Safety and antitumor activity of the multitargeted pan-TRK, ROS1, and ALK inhibitor entrectinib: combined results from two phase I trials (ALKA-372-001 and …

A Drilon, S Siena, SHI Ou, M Patel, MJ Ahn, J Lee… - Cancer discovery, 2017 - AACR
Entrectinib, a potent oral inhibitor of the tyrosine kinases TRKA/B/C, ROS1, and ALK, was
evaluated in two phase I studies in patients with advanced or metastatic solid tumors, including …